Market research
OC9.F Omnicell, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- 40.56
- Analyst target
- 167.5
- Dividend yield
- Not available
- Beta
- 0.97
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- US68213N1090
- Market cap
- 1B
- P/E ratio
- 40.56
- Analyst target
- 167.5
- Dividend yield
- Not available
- Beta
- 0.97
About
About Omnicell, Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OC9.F discussion.
5 years, 5 months ago
Omnicell, Inc is currently in a long term uptrend where the price is trading 23.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Omnicell, Inc's total revenue rose by 0.4% to $249M since the same quarter in the previous year.
Its net income has dropped by 25.9% to $16M since the same quarter in the previous year.
Finally, its free cash flow grew by 255.8% to $71M since the same quarter in the previous year.
Based on the above factors, Omnicell, Inc gets an overall score of 4/5.